Immunotherapy before liver surgery for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving immunotherapy (atezolizumab) before liver surgery helps your body fight liver cancer more effectively. It's for people with early-stage liver cancer who are already scheduled for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (HCC) and are scheduled for liver surgery.
- You are 18 years or older.
- If you can become pregnant, you agree to use birth control during the trial and for 5 months after the last treatment.
- You have not had a bad allergic reaction to immunotherapy before.
- You are not pregnant or breastfeeding.
- You have no serious heart or lung problems that would make surgery unsafe.
- Your hepatitis B, C, or HIV is under control with medication (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two immunotherapy drugs (sintilimab and ipilimumab) with standard procedures to block or destroy the tumor's blood supply can help keep liver cancer from returning after surgery. It is for people whose liver cancer can be removed but has a higher risk of coming back.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This study looks at the risks of surgery in people with liver cancer who received immunotherapy before or instead of surgery. It aims to understand how safe and effective this approach is.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This trial tests whether giving two drugs (tislelizumab, an immunotherapy, and lenvatinib, a targeted therapy) before surgery helps patients with small liver cancers in tricky locations. The goal is to shrink the tumor and improve surgical outcomes compared to surgery alone.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.